### Guideline Page and Request

**NSCL-24/NSCL-F 2 of 4**

External request: Submission from Merck and Co requesting review of the data and consideration of inclusion of pembrolizumab in combination with carboplatin and pemetrexed as initial therapy for previously untreated, advanced non-squamous non-small cell lung cancer (NSCLC) patients whose tumors lack epidermal growth factor receptor sensitizing mutations or anaplastic lymphoma kinase translocations.

### Panel Discussion

Based upon review of the data in the references noted in the submission, the panel consensus was to make no changes to the current recommendations. Insufficient data to support inclusion.

### References

See submission for references.

### Institutional Vote

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Abstain</th>
<th>Absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21</td>
<td>1</td>
<td>3</td>
</tr>
</tbody>
</table>